Stephan Pflugbeil1, Karin Böckl2, Reinhold Pongratz1, Marianne Leitner3, Winfried Graninger4, Astrid Ortner5. 1. Division of Rheumatology, ÖGK Outpatient Department of Graz, 8010, Graz, Austria. 2. Institute of Pharmaceutical Sciences, University of Graz, 8010, Graz, Austria. 3. Hospital Pharmacy, Medical University of Graz, 8036, Graz, Austria. 4. Department of Rheumatology, Medical University of Graz, 8036, Graz, Austria. 5. Institute of Pharmaceutical Sciences, University of Graz, 8010, Graz, Austria. astrid.ortner@uni-graz.at.
Abstract
BACKGROUND: Treating patients with inflammatory joint diseases (rheumatoid arthritis, psoriatic arthritis) according to established treatment algorithms often requires the simultaneous use of three or more medications to relieve symptoms and prevent long-term joint damage as well as disability. OBJECTIVE: To assess and give an overview on drug-drug interactions in the pharmacotherapy of inflammatory joint diseases with regards to their clinical relevance. METHODS: All possible drug combinations were evaluated using three commercially available drug interaction programs. In those cases where only limited/no data were found, a comprehensive hand search of Pubmed was carried out. Finally, the drug-drug interactions of all possible combinations were classified according to evidence-based medicine and a specifically generated relevance-based system. RESULTS: All three interaction software programs showed consistent results. All detected interactions were combined in clearly structured tables. CONCLUSION: A concise overview on drug-drug interactions is given. Especially in more sophisticated cases extensive knowledge of drug interactions supports optimisation of therapy and results in improved patient safety.
BACKGROUND: Treating patients with inflammatory joint diseases (rheumatoid arthritis, psoriatic arthritis) according to established treatment algorithms often requires the simultaneous use of three or more medications to relieve symptoms and prevent long-term joint damage as well as disability. OBJECTIVE: To assess and give an overview on drug-drug interactions in the pharmacotherapy of inflammatory joint diseases with regards to their clinical relevance. METHODS: All possible drug combinations were evaluated using three commercially available drug interaction programs. In those cases where only limited/no data were found, a comprehensive hand search of Pubmed was carried out. Finally, the drug-drug interactions of all possible combinations were classified according to evidence-based medicine and a specifically generated relevance-based system. RESULTS: All three interaction software programs showed consistent results. All detected interactions were combined in clearly structured tables. CONCLUSION: A concise overview on drug-drug interactions is given. Especially in more sophisticated cases extensive knowledge of drug interactions supports optimisation of therapy and results in improved patient safety.
Entities:
Keywords:
Drug combination; Drug interaction; Pharmacotherapy; Psoriatic arthritis; Rheumatoid arthritis
Authors: A Lanas; L A García-Rodríguez; M T Arroyo; F Gomollón; F Feu; A González-Pérez; E Zapata; G Bástida; L Rodrigo; S Santolaria; M Güell; C M de Argila; E Quintero; F Borda; J M Piqué Journal: Gut Date: 2006-05-10 Impact factor: 23.059
Authors: Stanley Cohen; Samuel H Zwillich; Vincent Chow; Robert R Labadie; Bethanie Wilkinson Journal: Br J Clin Pharmacol Date: 2010-02 Impact factor: 4.335
Authors: María Espinosa-Bosch; Bernardo Santos-Ramos; María Victoria Gil-Navarro; María Dolores Santos-Rubio; Roberto Marín-Gil; Paloma Villacorta-Linaza Journal: Int J Clin Pharm Date: 2012-09-11
Authors: Michael D Wiese; Matthew Schnabl; Catherine O'Doherty; Llewellyn D Spargo; Michael J Sorich; Leslie G Cleland; Susanna M Proudman Journal: Arthritis Res Ther Date: 2012-07-12 Impact factor: 5.156
Authors: Meghna Jani; Anne Barton; Richard B Warren; Christopher E M Griffiths; Hector Chinoy Journal: Rheumatology (Oxford) Date: 2013-08-14 Impact factor: 7.580